公开(公告)号：US20210069322A1

公开(公告)日：2021-03-11

申请号：US16772203

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  C12N15/86 ,  C07K14/02 ,  A61P31/20

Abstract: There is provided a method of treating chronic hepatitis B infection (CHB) in a human, comprising the steps of: a) administering to the human a composition comprising a replication-defective chimpanzee adenoviral (ChAd) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); b) administering to the human a composition comprising a Modified Vaccinia Virus Ankara (MVA) vector comprising a polynucleotide encoding a hepatitis B surface antigen (HBs) and a nucleic acid encoding a hepatitis B virus core antigen (HBc); and c) administering to the human a composition comprising a recombinant hepatitis B surface antigen (HBs), recombinant hepatitis B virus core antigen (HBc) and an adjuvant.

公开(公告)号：US20240382583A1

公开(公告)日：2024-11-21

申请号：US18609504

申请日：2024-03-19

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  A61K39/00 ,  A61K39/39 ,  A61P31/20 ,  C07K14/005 ,  C12N7/00

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

公开(公告)号：US20240131140A1

公开(公告)日：2024-04-25

申请号：US18276578

申请日：2022-02-09

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA ,  XIAMEN INNOVAX BIOTECH CO., LTD.

Inventor： Babak BAYAT ,  Véronique HENDERICKX ,  Bram VUYLSTEKE

IPC: A61K39/12

CPC classification number: A61K39/12 ,  A61K2039/55505 ,  C12N2710/20034

Abstract: Described are methods for the preparation of a HPV vaccine composition by, for example (i) adsorbing one or more HPV antigen(s) on a metallic salt and, then (ii) adding a non adsorbed glycolipid based TLR4 ligand to the mixture obtained in (i). Resulting HPV vaccine compositions and uses thereof are also described.

公开(公告)号：US20210154290A1

公开(公告)日：2021-05-27

申请号：US16772194

申请日：2018-12-14

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Virginia AMMENDOLA ,  Babak BAYAT ,  Clarisse LORIN ,  Ventzislav Bojidarov VASSILEV ,  Alessandra VITELLI

IPC: A61K39/29 ,  C12N7/00 ,  C07K14/005 ,  A61K39/39 ,  A61P31/20

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.